SYF96e57766bfab46f7ba47cdba66d8a9a7Registry ID: 2024-513155-32-00|RecruitingPhase 2
Loading search results
interventional
N/A
1 country
1
To assess the change in UAS (Urticaria Activity Score) 7 from baseline to week 20.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 3, 2025
Actual (reported)Difference in the UAS7 score from baseline to week 20.
Difference of VAS pruritus score between baseline and week 20.
Difference in the UCT score between baseline and week 20.
Difference in the VAS disease activity score from baseline to week 20.
Proportion of patients achieving a ≥50% reduction in UAS7 score from baseline to week 20.
Proportion of patients achieving a UAS7 score < 6 at week 20.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Ilumetri 200 mg solution for injection in pre-filled syringe
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Ilumetri 200 mg solution for injection in pre-filled syringe
Named ingredient: tildrakizumab
View registry recordPhilipps-Universitaet Marburg
Marburg, 35043, Germany
Study Coordinator
First Submitted
July 3, 2025
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.